today. and joining everyone thank you afternoon us for Good Vince. Thanks
discussed to going from have both the and to the population means is, any focus simply, where always physiological a driving all been can we benefit to and and This common As to from types diseases, it. getting has treating anatomical technology it Put our who body. in part of bring disease standpoint. means our a and rare, past, patients of standpoint
As such, we populations to various the production products by capabilities, address expand are improving scaling our constantly and convenience, of reach working administration dosing to schedule. optimizing our
targets We many make the reach new believe we of that constantly targeting treatment muscle. and TRiMTM and world many that years to have conditions to and types and the also proteins, validation adequate with to We skeletal striving have the to reach addressing have that are areas now and without only rare reality. of that silence We chronic proprietary options. distinct platform cell gaining RNAi third high and RNAi indications ago disease, such are was By HBV committed potentially our Arrowhead to even to of innovation cell cystic not clinical diseases always been body quarter diseases. fibrosis a on this clinical new It the and disease four be cusp showing and devoted considerable gene strive expand candidates year, that tumor, the rarer prevalence long we and and such to can throughout only for lung, relevant reaching AAT to as address then conditions expect disease. liver at different types, liver-expressed cardiovascular may as resources in thought effort
CF to to and with and have patients, to risk three these patients AAT expected types of data patients patients models those ARO-AAT liver ARO-ENAC data FSHD. pharma three. volunteers that potential of big not value that, in be with of ability and positions animal how a the including: in potential creation hundreds at data all and in says months, of been less a long-term, areas; of employees in data NASH the small and that XXX a ARO-HSD is It one not in data and with Three ARO-HIFX disease, than what tens number about value of mid, cell readouts cusp Think is breakthrough data relate in it thousands market healthy a may expect of may lead about over We couple our to NASH, billions nearing cell data-rich knowledge, $X and breakthrough employees renal value of having us on near, next Arrowhead field. in these addressed RNAi innovate in approximately with in be our market our for and by humans. in that carcinoma of ARO-DUXX for this billion it successfully a
in has with programs development. already pipeline undisclosed clinical studies, in candidates Our six additional preclinical liver directed
In last it. on type addition, same higher probability a lower provides the couple we this each We risk clinical builds other that once believe program in each seen achieve than validation, you’ve from and the candidate years, as over learnings cell successive of modalities. profile went success before
years. double potentially the We expect over our size few pipeline in to next
dramatically. the for new XX our to potential us and cell serve. we access months, growth We future future We the the expanding pipeline, continue leverage a this RNAi XX our represents field company, the Arrowhead hope type to and also so rapidly months about our for to for we that broadly. every It’s expand confidence will gives patients believe this believe hope of to
for progress value making near-term. the key pipeline in programs the potential current with our We’re drivers substantial on also
a of these. about Let’s few talk
review, us, results to some our exciting acceptance, some from the improvements a and community. biomarkers in improvements the monomer medical globule study, the liver want the last consistent treatment led to histological meeting, at XX-month pending in fibrosis; investigators ARO-AAT demonstrated dataset XXXX an of we relevant biopsy We announced in I health. ARO-AAT partners context. fuller and that abstract in were of both a label decrease the Z-AAT mutant of intra-hepatic a reduction to burden; First, consistent present in open study and results to to the results other substantial but intend and Takeda, at patient week. To upcoming These incredibly protein, polymer; provide
cirrhosis fibrosis achieved observed: four stages with during fifth stage, XX% after results of stage Two patients were assessment improvement in patients. with the the these patients one After important histological XX a to decreased XX patients the only stage globule decreased no histological in following reductions globule assessment demonstrated observed: fibrosis other to improvement a of of in worsening total results. worsening of want All treatment, Specifically, and, following and, fibrosis XX% baseline. one to by Metavir at of The two had the four in the weeks patients Z-AAT points highlight by improved two treatment intra-hepatic in or fibrosis XX%. with demonstrated or reductions patient. cohort total Metavir All five ARO-AAT Four achieved X, the of scores; results greater were greater intra-hepatic patients in scores; stage, weeks Z-AAT about fibrosis no few treatment in a five XX%. who I
were remarkably consistent. results the First,
patients what response studied. deeply is do in seeing it in expression, designed all have terms a to that that rate We XXX% was Z-AAT of reducing are been doing indicating ARO-AAT
new amazing is Z-AAT heal. the that ability saw rapidly Second, we protein to liver as silenced, has an
believe I for is XX they and disease, faster is than As other months dramatic XX% received healing grew been than this of hepatitis. of patients six such This a and XX% when to saw we who more I and only in has patients mentioned, treatment. regression for diseases as months received treatment of it NASH expected faster fibrosis, and of liver this shown viral
Based important potential stage the from of in data two humans our late-stage that disease disease, in that even which ARO-AAT six that The disease. the patients this FX animal after could on are been with is type of we with patients of I improve that point we fibrosis and months FX disease started improved from is treatment. The cirrhosis, trial Metavir believe work to support with third studied first only or rarely extensive the models, heal of to regardless in belief. rescue FX any liver this believed that late-stage has demonstrated have These cirrhosis, liver outcomes rapidly. stage, cirrhosis advanced rapidly.
In addition, and the to safety be consistent positive continue reports. assessments with previous
for protein and by is appears of a be augmentation is discontinuations is the biology crystal that therapy, to studied and an therapy. to clear. well monogenic efficiently seeks cannot We other on in had programs. function, whose required is other of those a date, into of Alpha-X accumulation ultimately is drug, have no caused regular that cause liver-directed due get is to globules, What consistent measures disease our aggregation lung is of with fibrosis. patients protein no ZAAT reverse and This by in was expectation insult. form example liver those great leads out polymers RNAi-based than study not have inflammation, augmentation which understood. target disease to the hepatocytes. cascade patients to to smart intervention. well-tolerated liver selection ARO-AAT ARO-AAT a already our changes generally It the that This entered do ARO-AAT any meaningful removing the cascade the of clinically mutant
strong that every ability indicate they encouraging forward improve heal, and is goal regulatory a to data liver believe we year. in a later to help path accelerated and We potential results, resilient ARO-AAT cascade. seek support to our to step interacting look organ with authorities with a this the approval. to Our These are appears the could
our Olpasiran, are AMG made ARO-AAT, to wholly called In good was which also These addition we’ve ARO-APOCX licensed owned, which Amgen. cardiometabolic programs. and are and ARO-ANGX, on XXX, progress formerly to
in recently to complete On first of lipoprotein(a) XXXX. in in disclosed elevated data enrollment is Phase with study the quarter, with expected program, half patients this latter Amgen X the expected a that be
IND programs. to the active, completed ARO-APOCX initiate four reviewed or ARO-ANGX, by in we which and two studies now intend are we For and were across FDA the United filings the more and States,
on but We each are here and the we targeting. will give running, designs are when the study up patient gets that more populations detail
patients XXX X which is over triglycerides focused Xb or ARO-APOCX, in mg/dL; mg/dL we Phase with in mg/dL; FCS. familial triglycerides For A hypertriglyceridemia, study patients Xb between three A Phase with XXX with studies: study intend syndrome, study patients to chylomicronemia Phase XXX and, in on a with patients start
is and with Xb elevated intend LDL we characterized triglycerides dyslipidemia For by mixed focused Phase a cholesterol, to start ARO-ANGX, elevated patients which on study.
For specific about we focused also the four mentioned to questions compounds, on additional we exploring studies are the smaller are but just are programs, primary the first. answer studies both initiating
in of to no also in ARO-DUXX myotoxic gene specific targets announced currently events protein, liver, are genetic of muscle clearance expression discuss muscle. target the we We specifically announcement of pipeline, ARODUXX. causes potential bring for, lead and which to gene intend near-term This is the facioscapulohumeral expectations built DUXX validation. X to of We as third but which There platform. FSHD. FSHD. are maintain timing dystrophy, a can is as want the and muscular DUXX, made that to clear for studies is the epigenetic targeted to there leads for and first I DUXX complete or encodes to strong DUXX, select associated overexpression TRIM across outside key is file strategy perfectly not homeobox biologic the or genetic Arrowhead’s quarter we for with weeks on begin to on disease effective regulatory with a candidate of Before clinical only designed FSHD few an our treatments fits highlight of patients to muscle our to believe double RNAi failure ARO-DUXX XXXX degeneration. human with suppression that I diseases treatment ago. a
and to so on to June on focus our planned It’s next very near I’m July. several going readouts. Let’s the for few to true especially This is a with be move busy mid-term. going months, events expectations and time and potentially important events the for for
from study results of initial order: the Ascending X. lavage, additional this Society study; Report Congress; second results important a in thereafter; deep continued X. IND-enabling preclinical Phase X. first couple host we in the stage. ARO-APOCX that plate of ARO-ENaC and a expect the near-term, into received study, the interim a programs X. results healthy just preclinical do with the and the first-in-human full to in patients first-in-human healthy knockdown initial have and open-label Report study; study. development Single we File XXXX FCS the on market initial regular with Phase X disease, X. in in AROAAT; first study discuss events data volunteers, cohort going that in and pulmonary the are following patients shortly potential that over XXXX and, data the International patients potentially space in and in already full Announce include This very Phase X. results bronchial FSHD likely at forward. with These Xb data path; biopsy patients from from Xb will clearly of Phase the results Research Dose expect study; the a the Report next a X. development gene the and are the XX-month expect ARO-HSD safety Dose months. We We first-in-human catalysts roughly the the from and Dose the interim first to Xb from ARO-ANGX the ARO-DUXX interim planned Fibrosis; webinar CTA Cystic the KOL Report ARO-HIFX the ARO-DUXX brushings in X. opportunity, first cohort Present for volunteers X. for
been efficiently, from will that to thrilled larger as DNA still of as part the San principles and have that are to to organization. Arrowhead see to the Martin. can continue speed, over Dr. be the and expanding call of even Javier to efficiency our execute a growing these With overview, like company. now Javier? I’d precision, turn in a culture beginning Innovation, have support capital We hallmarks pipeline been and this R&D we
